Philip Morris International Announces Appointment of Two Former U.S. FDA Officials, Highlighting the Company’s Continued Commitment to Smoke-Free Product Science and Regulation
Philip Morris International Inc. (PMI) (NYSE: PM) announced today that it has appointed two former United States Food and Drug Administration (U.S. FDA) officials to key positions to accelerate its science-based transformation.
Dr. Badrul Chowdhury is appointed PMI’s Chief Life Sciences Officer, Smoke-Free Products, succeeding Jorge Insuasty, who will complete his move into the recently created position of President, Vectura Fertin Pharma. After a short transition period, Badrul will join PMI’s Senior Management Team in January 2023, reporting to Jacek Olczak, Chief Executive Officer.
“I am delighted to welcome Badrul to PMI and look forward to working closely with him as he leads our talented team of scientific experts,” said Jacek Olczak. “He is an accomplished scientist and regulatory strategist, with decades of leadership experience, both in industry and as a regulator within the U.S. FDA’s Pulmonary Division. His wealth of knowledge and experience will be critical to help achieve our ambition of a smoke-free future. I also extend my sincere thanks to Jorge Insuasty for his contributions to the function as he moves to oversee Vectura Fertin Pharma full-time.”
Dr. Chowdhury joins PMI from a U.S.-based biotech company developing inhalation products for rare respiratory diseases, where he was Chief Medical Officer. Prior to that, he was AstraZeneca’s Senior Vice President and Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late-Stage Development in Biopharmaceuticals R&D. Before joining the pharmaceutical industry, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. FDA for almost 21 years, from 1997 to 2018, providing scientific and regulatory oversight of therapies for lung, autoimmune, and inflammatory diseases. Dr. Chowdhury is a medical doctor and holds a PhD in immunology.
“Joining the PMI team is an exciting new adventure,” said Dr. Chowdhury. “The investment the company has already made in delivering high-quality science to support its transformation and smoke-free vision is unprecedented. I am thrilled to have the chance to help move the company forward faster and to truly seize the public health opportunity that well-regulated smoke-free products present. I look forward to working with the Senior Management Team and the entire Life Sciences function to accelerate progress.”
Dr. Matthew (“Matt”) Holman is appointed as PMI’s Vice President of U.S. Scientific Engagement and Regulatory Strategy, reporting to Deepak Mishra, President of PMI Americas.
“We are delighted that Matt will be joining PMI to further accelerate our journey toward a smoke-free future, particularly here in the United States,” said Deepak Mishra. “As we transform, we recognize the importance of bringing together diverse perspectives, including those of regulatory bodies and the scientific community. Matt’s solid scientific and stakeholder knowledge, combined with his passion for tobacco harm reduction, will be invaluable.”
Dr. Holman joins PMI from the U.S. FDA, where he served for more than 20 years, most recently as Director of the Office of Science at the Center for Tobacco Products (CTP). At CTP, Holman was instrumental in building the FDA’s marketing application review programs. He served as CTP’s chief scientist, playing a significant role in guiding policy decisions, developing rulemaking and guidance documents, and overseeing a robust regulatory science research program for tobacco products. Previously, Holman worked at the FDA’s CDER on over-the-counter drug products, including as Deputy Director of the Division of Nonprescription Regulation Development. He received his PhD in biochemistry from the University of Maryland at College Park.
“Having spent more than two decades working to improve public health as a regulator, I am delighted to join forces with PMI, a company that is firmly committed to the goal of accelerating the end of smoking,” said Dr. Holman. “PMI is leading the industry in a major transformation that can ultimately provide an unprecedented breakthrough for public health. I’m excited to make this move and join PMI on its smoke-free journey.”
The appointment of these seasoned scientific and regulatory experts complements the recent hiring of Keagan Lenihan, who joined PMI in May 2022 as Vice President of Government Affairs and Public Policy, and Head of its D.C. office. Lenihan spent two decades working in government, corporate, and public policy, including as Associate Commissioner for External Affairs and Strategic Initiatives and then Chief of Staff at the U.S. FDA.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free products were available for sale in 70 markets, and PMI estimates that approximately 13.2 million adults around the world had already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Philip Morris International
T. +41 (0)58 242 4500
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei Publishes First White Paper on Approaches to Fairness, Equity & Opportunity2.12.2022 04:07:00 CET | Press release
Huawei called on the ICT industry players to create a level playing field for all people, not just their own employees in its first White Paper on Approaches to Fairness, Equity & Opportunity at their Women in Tech event held at the Peter Drucker Forum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201006045/en/ (Graphic: Business Wire) This White Paper is part of Huawei's ongoing campaign aimed at increasing digital skills education and access for women across the world. Huawei, like many other companies within the ICT industry, has advocated on fairness, opportunity, and equity within their own operations. Notably, the company has taken measurable steps to increase diversity in their workforce and increase internal representation of marginalized groups. It is widely understood that significant, tangible results from such programs are often slow to materialize. And thus Huawei has focused many of its efforts beyond the
H&M and Webhelp Finalize Acquisition of H&M’s Nuremberg Customer Service Center1.12.2022 16:29:00 CET | Press release
The responsible authorities have officially approved the transfer of fashion brand H&M’s Nuremberg customer service center to Webhelp, a leading global customer experience BPO player. The companies, having already signed an agreement in this regard on 19 October 2022, will see Webhelp operate the service center from 1 December onwards under its own name. With this acquisition, Webhelp doubles the number of its employees in Nuremburg and is now one of the largest employers in the industry in northern Bavaria. Today, Webhelp employs more than 110,000 employees in over 60 countries. Webhelp's German headquarters in Nuremberg already provides an attractive working environment with state-of-the-art technical equipment for over 500 employees. Furthermore, Webhelp is committed to investing in the development and wellbeing of its customer advisors, known as 'game-changers,' around the world. Webhelp will welcome the 500 employees of the H&M Service center from today, 1 December, to the Webhelp
Morgan Stanley Sustainable Signals: New Survey Shows Opportunities Exist for Asset Managers to Better Meet Asset Owner Sustainable Investing Needs1.12.2022 16:00:00 CET | Press release
Asset managers have the opportunity to meet asset owners’ growing demands for sustainable investment practices, products and reporting, according to new research by the Morgan Stanley Institute for Sustainable Investing. The latest in the Firm’s Sustainable Signals series, this institutional investor survey polled 110 asset owners in North America, Europe and Asia, as well as 201 asset managers across the same regions to understand what asset owners want and what asset managers are offering—and where the gaps lie in delivering environmental, social and governance (ESG) solutions. “The results of our latest Sustainable Signals survey show that sustainable investing remains an important focus area for institutional investors globally, with the vast majority reporting an increased interest over the past two years,” said Jessica Alsford, Chief Sustainability Officer and CEO of the Institute for Sustainable Investing at Morgan Stanley. “At the same time, our findings show a significant oppo
Successful Product Innovations and Portfolio Acquisition Drive Wella Company to Exceed Profit and Growth Expectations in Successful Second Year1.12.2022 15:12:00 CET | Press release
Wella Company, a global leader in the $100 billion hair and nail segment of the beauty industry, is marking a successful second year as a standalone company, delivering year-over-year double-digit profit and growth ahead of expectations. In Fiscal Year 22, which closed at the end of June, Wella Company beat all targets on financial performance across the globe. Since its founding in December 2020, Wella Company has delivered continuous double-digit profit and growth ahead of expectations and is one of the fastest-growing beauty companies in the sector. Wella Company’s portfolio includes iconic professional and retail hair, nail, and beauty tech brands Wella Professionals, O·P·I, ghd, Briogeo, Nioxin, Sebastian Professional, and Clairol. “Our first two years of business have shown the enduring potential of the Wella Company portfolio – we are re-establishing category excellence in both hair and nails, and both professionals and consumers are falling in love again with our beautiful bran
Sermo Survey Finds Opportunity to Educate General Care Physicians on PrEP to Increase Patient Adoption1.12.2022 15:05:00 CET | Press release
Timed to World AIDS Day, Sermo, a physician-first online community and leader in global HCP insights, released a new survey that found 46% of general care physicians including PCPs, OB-GYNs, and pediatric physicians, reported they feel they do not have enough knowledge about currently approved PrEP medication options to prescribe them to patients. Whereas 98% of infectious disease specialists reported they felt they have enough knowledge about PrEP medications signaling a need for further education from industry stakeholders for noninfectious disease specialists. An important area of opportunity as patients who are likely good candidates for PrEP often go to a PCP instead of seeking out an infectious disease specialist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005355/en/ The cost of PrEP continues to be a driving factor for patients’ decision to decline treatment in the U.S. as reported by 26% of surveyed physici